Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 with chemoradiotherapy in unresectable locally advanced ESCC
NCT05490719Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2022
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, open-label trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Aug 2022; status: recruiting.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05490719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490719.